My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 136

    1.

    Systemic therapy for metastatic breast cancer.

    Haskell CM, Sparks FC, Graze PR, Korenman SG.

    Ann Intern Med. 1977 Jan;86(1):68-80.PMID: 835932 [PubMed - indexed for MEDLINE]Related articles

    2.

    Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.

    Hubay CA, Pearson OH, Marshall JS, Rhodes RS, Debanne SM, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL.

    Surgery. 1980 May;87(5):494-501.PMID: 7368100 [PubMed - indexed for MEDLINE]Related articles

    3.

    Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.

    Hubay CA, Gordon NH, Crowe JP, Guyton SP, Pearson OH, Marshall JS, Mansour EG, Hermann RE, Jones JC, Flynn WJ, et al.

    Surgery. 1984 Jul;96(1):61-72.PMID: 6740497 [PubMed - indexed for MEDLINE]Related articles

    4.

    Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.

    Hubay CA, Pearson OH, Manni A, Gordon NH, McGuire WL.

    J Steroid Biochem. 1985 Dec;23(6B):1147-50.PMID: 3912620 [PubMed - indexed for MEDLINE]Related articles

    5.

    Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

    [No authors listed]

    CMAJ. 1998 Feb 10;158 Suppl 3:S52-64. Review.PMID: 9484279 [PubMed - indexed for MEDLINE]Related articles

    6.

    Management of metastatic breast cancer.

    Haskell CM.

    Med Clin North Am. 1977 Sep;61(5):967-78. No abstract available. PMID: 330978 [PubMed - indexed for MEDLINE]Related articles

    7.

    Systemic treatment of breast cancer: past, present and future.

    Carbone PP.

    Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):759-67. No abstract available. PMID: 977407 [PubMed - indexed for MEDLINE]Related articles

    8.

    Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.

    Pearson OH, Hubay CA, Marshall JS, Gordon NH, McGuire WL, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C.

    Breast Cancer Res Treat. 1983;3 Suppl:S61-8.PMID: 6367862 [PubMed - indexed for MEDLINE]Related articles

    9.

    Management of breast cancer.

    Cohen IA, Keller JH, Abate MA.

    Clin Pharm. 1982 Nov-Dec;1(6):515-29. Review.PMID: 6192963 [PubMed - indexed for MEDLINE]Related articles

    10.

    Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study.

    J Clin Oncol. 2002 Dec 15;20(24):4628-35.PMID: 12488406 [PubMed - indexed for MEDLINE]Related articles

    11.

    Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.

    Hubay CA, Pearson OH, Marshall JS, Rhodes RS, Debanne SM, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL.

    Eur J Cancer. 1980;Suppl 1:189-95. No abstract available. PMID: 7032932 [PubMed - indexed for MEDLINE]Related articles

    12.

    Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

    Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG.

    J Clin Oncol. 1996 Jul;14(7):1982-92.PMID: 8683228 [PubMed - indexed for MEDLINE]Related articles

    13.

    Overview of resistance to systemic therapy in patients with breast cancer.

    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

    Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

    14.

    Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update.

    Glick JH, Fowble BL, Haller DG, Rosato EF, Mackie JA, Weiler C, Glover DJ, Fox KR, Hurwitz S, Goodman RL.

    NCI Monogr. 1988;(6):297-301.PMID: 3352774 [PubMed - indexed for MEDLINE]Related articles

    15.

    Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.

    Chang JC, Wergowske G.

    Cancer. 1981 Dec 1;48(11):2503-6.PMID: 7296498 [PubMed - indexed for MEDLINE]Related articles

    16.

    Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

    Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U.

    Breast Cancer Res Treat. 1985;5(2):95-115.PMID: 3839424 [PubMed - indexed for MEDLINE]Related articles

    17.

    Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.

    Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G.

    Ann Oncol. 2005 Sep;16(9):1449-57. Epub 2005 Jun 14.PMID: 15956037 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.

    Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM.

    Cancer Treat Rep. 1978 Nov;62(11):1685-92.PMID: 728894 [PubMed - indexed for MEDLINE]Related articles

    19.

    Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

    Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L; Cancer and Leukemia Group B.

    J Clin Oncol. 2003 May 1;21(9):1825-35. Erratum in: J Clin Oncol. 2003 Dec 1;21(23):4469. PMID: 12721260 [PubMed - indexed for MEDLINE]Related articles

    20.

    Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

    Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

    Ann Oncol. 2003 Jun;14(6):833-42. Review.PMID: 12796019 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity